{
    "ticker": "AUTL",
    "name": "Autolus Therapeutics plc",
    "description": "Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing next-generation, programmed T cell therapies for the treatment of cancer. Founded in 2014 and headquartered in London, UK, Autolus is dedicated to harnessing the power of the body's immune system to fight cancer. The company is pioneering a new class of T cell therapies that utilize its proprietary programming technologies to enhance the efficacy and safety of treatments. Autolus is working on various product candidates, including its lead candidate, AUTO1, which targets B-cell malignancies, and other innovative programs aimed at solid tumors. The company's mission is to transform the treatment landscape for cancer patients by delivering advanced therapies that can achieve better outcomes than current standard-of-care options. Autolus is committed to advancing its pipeline through rigorous clinical trials and has built a strong intellectual property portfolio to protect its innovations. With a team of experienced scientists and industry veterans, Autolus aims to redefine the boundaries of cancer treatment and improve the lives of patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2014",
    "website": "https://www.autolus.com",
    "ceo": "Dr. Christian Itin",
    "social_media": {
        "twitter": "https://twitter.com/AutolusTx",
        "linkedin": "https://www.linkedin.com/company/autolus-therapeutics"
    },
    "investor_relations": "https://investors.autolus.com",
    "key_executives": [
        {
            "name": "Dr. Christian Itin",
            "position": "CEO"
        },
        {
            "name": "Aisling Burnand",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "T Cell Therapies",
            "products": [
                "AUTO1",
                "AUTO3"
            ]
        }
    ],
    "seo": {
        "meta_title": "Autolus Therapeutics plc | Next-Gen T Cell Therapies for Cancer",
        "meta_description": "Explore Autolus Therapeutics, a leader in programmed T cell therapies aimed at transforming cancer treatment. Learn about our innovative pipeline and commitment to patients.",
        "keywords": [
            "Autolus",
            "T Cell Therapies",
            "Cancer Treatment",
            "Biotechnology",
            "Immunotherapy"
        ]
    },
    "faq": [
        {
            "question": "What is Autolus known for?",
            "answer": "Autolus is known for developing next-generation programmed T cell therapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Autolus?",
            "answer": "Dr. Christian Itin is the CEO of Autolus Therapeutics."
        },
        {
            "question": "Where is Autolus headquartered?",
            "answer": "Autolus is headquartered in London, United Kingdom."
        },
        {
            "question": "What are Autolus's main product candidates?",
            "answer": "Autolus's main product candidates include AUTO1 and AUTO3, targeting various cancers."
        },
        {
            "question": "When was Autolus founded?",
            "answer": "Autolus was founded in 2014."
        }
    ],
    "competitors": [
        "CRSP",
        "KITE",
        "ZIOP"
    ],
    "related_stocks": [
        "BMY",
        "JNJ",
        "GILD",
        "AMGN"
    ]
}